|
Join us in accelerating research and advancing treatment for the more than 1 billion people worldwide living with obesity. |
|
BREAKING NEWS: Endocrine Society releases Scientific Statement on what's next in obesity science. COMING SOON: Clinical Practice Guideline (CPG) on Pharmacologic Management of Obesity (coming 2027) |
Medicare Bridge Program: In July, the Centers for Medicare and Medicaid Services (CMS) launched the Medicare Bridge Program, which provides eligible Medicare beneficiaries with access to certain GLP-1 medications. The Society has additional information and resources about this new program.
Join Clinical Endocrinology Update (CEU) 2026 online Oct. 22-24 for various sessions on obesity and weight management, including those that addresses GLP-1-induced sarcopenia and preventing post-treatment weight regain.
Journal of the Endocrine Society, September 2026: "A single dose trial of mizagliflozin for the treatment of postbariatric hypoglycemia" Postbariatric hypoglycemia (PBH) is a complication of bariatric surgery characterized by severe postprandial hypoglycemia for which there is no approved therapy. This article will be the subject of an upcoming Endocrine Feedback Loop episode.
Amy E. Rothberg, MD, the Society’s Obesity Task Force Chair, discusses the importance of addressing this public health epidemic and the Society’s record of leadership in obesity.
Research & Publications
(Thematic Issue) Obesity and Metabolic Health: Editors of The Journal of Clinical Endocrinology & Metabolism, Endocrinology, Journal of the Endocrine Society, JCEM Case Reports, and Endocrine Reviews selected recently published articles that advance the understanding of obesity and roles of diet and exercise on metabolic health.
The important role of comorbidities in the management of obesity | JES
Loss of the calorie restriction response protein DEPP1 worsens diet-induced obesity | Endocrinology
Epigenetics and childhood obesity: DNA methylation coordinates environment and gene regulation | Endocrine Reviews
A New EHR-Based Measure Could Improve Population Health Outcomes | Endocrine News
Advocacy & Community
The Obesity Playbook (Updated September 2026) includes up-to-date facts and figures, state of the science, policy recommendations, and a list of Endocrine Society members who are experts in the field of obesity..
Obesity Special Interest Group (SIG): Members interested in obesity education, research, networking activities, and more.
OMB Federal Assistance Rule Advocacy Campaign: Protect obesity research funding from OMB Proposed Rule.
2026 Obesity Fellows Program: Obesity Fellows program, September 18-19, 2026, is an exclusive, application-based, educational activity. Educational content from the program, including an open-access accredited on-demand course, will be available in December 2026 for endocrinologists and other healthcare professionals interested in obesity care.
CEU 2026: Strategies for Obesity and Weight Management: Clinical Endocrinology Update (CEU) 2026 sessions, online Oct. 22-24, addresses GLP-1-induced sarcopenia and preventing post-treatment weight regain.
Two Generations, One Challenge: Confronting Obesity in Pregnancy and Childhood's Metabolic Outcomes: Virtual webinar.
Reprogrammed by Chemicals: The Epigenetic Link Between Environmental Exposure and Obesity: Member-only webinar sponsored by the Society’s Obesity and EDCs Special Interest Groups.
ENDO 2026 Research: Tirzepatide May Affect Body’s Energy Use: The anti-obesity medication tirzepatide activates brown adipose tissue, according to research presented at ENDO 2026. Researcher Rok Herman, MD, discusses the results.
Taste Changes with Semaglutide: Endocrine Feedback Loop podcast examining whether semaglutide alters taste recognition, tongue gene expression, and brain responses to food-related cues.
Step Counts Decline Among GLP-1 Users ENDO 2026 video of researcher discussing findings that people who lost weight with GLP-1 anti-obesity medications tended to log fewer daily steps.
Funding for the Center on Obesity was provided in part through support by Eli Lilly and Company.
We are at the forefront of research and clinical practice using new hormone-based therapies, including GLP-1 based medications, to treat obesity and related medical problems.
